Edgewise Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Welcome everyone to the 41st Annual JPMorgan Healthcare Conference. My name is Tess Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Taylor Hanley and Adhiraj Chauhan from the team. Our next presenting company is Edgewise. And presenting on behalf of the company, we have CEO Kevin Koch.
(Conference Instructions) But with that, I'm going to hand it over to Kevin.
Okay. Thank you, Tess. Thank you, Taylor. JPM team. So thank you all for joining today.
This is my disclaimer for what I'm going to say today. So Edgewise, very experienced team from well-known companies: Array BioPharma, Genzyme, MyoKardia, Glaxo, Alexion, one of the most experienced teams in the industry. We use our platform to invent new drugs, oftentimes are for the most part, not entirely novel targets.
Our first drug candidate 5506, we believe can be a foundational medicine for the treatment of several muscular dystrophies. That
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
